Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 42Other hematologic neoplasm 39Lymphoid 39Thoracic 31Myeloid 22Genitourinary 22Breast 22Plasma cell 17Gynecologic 14Classical hematology 14Dermatologic 12Sarcoma 8CNS 8Other solid neoplasm 7Head & Neck 5Endocrine 5Tumor-Agnostic 4NET 2

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma 1

Interventions

trastuzumab deruxtecan 1pembrolizumab 1margetuximab 1lenvatinib 1atezolizumab 1Trastuzumab 1Pemetrexed 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has announcements × Tumor-Agnostic × Clear all
NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed
624 enrolled 17 charts 1 FDA
Tumor-Agnostic

Neoplasm Metastasis

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT02367781 2021-08-09

IMpower130

Hoffmann-La Roche

Phase 3 Completed
723 enrolled 28 charts 1 FDA
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡